Publications by authors named "L V Laing"
Article Synopsis
- Industrial pollution, particularly from mining, has led to significant metal contamination in some rivers in southwest England, yet brown trout are adapting to these harsh conditions.
- Researchers conducted genomic and transcriptomic analyses of trout populations from both metal-impacted and control rivers, discovering genetic differences and evidence of natural selection at various loci associated with metal tolerance.
- The study found that metal-impacted trout exhibited higher levels of harmful metals in their tissues and identified many differentially expressed genes related to detoxification, ion transport, and stress response, indicating an adaptive response to environmental pollution.
: The PI3K/AKT/mTOR (PAM) pathway is frequently activated in gynecological cancers. Many PAM inhibitors selectively target single PAM pathway nodes, which can lead to reduced efficacy and increased drug resistance. To address these limitations, multiple PAM pathway nodes may need to be inhibited.
View Article and Find Full Text PDFArticle Synopsis
- Metastatic castration-resistant prostate cancer (mCRPC) often shows loss of sensitivity to androgen receptors and activation of the PI3K/AKT/mTOR pathway, making treatment difficult due to feedback mechanisms that lead to drug resistance.
- The study suggests that gedatolisib, a potent multi-target inhibitor of the PI3K pathway and mTORC1/2, is more effective than single-node PAM inhibitors for treating prostate cancer cells, regardless of their PTEN/PIK3CA status.
- Gedatolisib's superior effectiveness arises from its ability to impact critical cell functions, and it is currently in a clinical trial combined with darolutamide for patients with mCRPC.
Article Synopsis
- The PAM pathway, often disrupted in breast cancer, involves interlinked signaling that supports tumor growth, and current treatments typically target only one part of this pathway.
- Researchers propose that gedatolisib, a pan-PI3K/mTOR inhibitor, could be more effective than single-node PAM inhibitors by addressing multiple targets, potentially reducing drug resistance in breast cancer cells.
- In laboratory tests, gedatolisib showed superior anti-cancer effects compared to other PAM inhibitors by decreasing cell survival and invasive behavior across various breast cancer cell lines, leading to further clinical evaluation in a Phase 3 study.
Article Synopsis
- Researchers are exploring new artemisinin triple combination therapies to combat artemisinin-tolerant strains using combinations of artemisone or other amino-artemisinins, a redox-active drug, and a third drug with a different action.
- Three potential redox partners have been evaluated: AD01, PhX6, and DpNEt, with PhX6 showing the most promising pharmacokinetic profile and efficacy against CQ-sensitive and resistant strains.
- Future studies will expand drug combinations to include artemiside and test the effectiveness of artemisone with PhX6 and the related compound SSJ-183.